ONCAlert | Upfront Therapy for mRCC

Latest NewsMORE >>

Data from the phase Ib/II CARTITUDE-1 trial that were presented at the 2019 ASH Annual Meeting demonstrated the anti-BCMA CAR T-cell therapy JNJ-4528 achieved a 100% overall response rate with responses in 29 patients with heavily pretreated relapsed/refractory multiple myeloma.
 
Feature:

Coverage from the 2019 Society for NeuroOncology Annual Meeting

 Learn More >>

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.